Standardizing steroid protocols for newly diagnosed inflammatory bowel disease patients: A quality improvement initiative

被引:0
|
作者
Lendner, Nuphar [1 ]
Perry, Sharon [2 ]
Sferra, Thomas J. [2 ]
Moses, Jonathan [3 ]
Young, Denise D. [2 ,4 ]
机构
[1] Pediatrix Gastroenterol Rocky Mt, Denver, CO USA
[2] UH Rainbow Babies & Childrens Hosp, Div Pediat Gastroenterol Hepatol & Nutr, Cleveland, OH USA
[3] Stanford Univ, Sch Med, Div Pediat Gastroenterol, Palo Alto, CA USA
[4] 11100 Euclid Ave,Mailstop RBC 6004, Cleveland, OH 44106 USA
关键词
adalimumab; corticosteroids; Crohn disease; infliximab; ulcerative colitis; CROHNS-DISEASE; MEDICAL RECORD; VALIDATION; MANAGEMENT; TRENDS;
D O I
10.1002/jpn3.12246
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
ObjectivesSystemic steroids can be used for induction of inflammatory bowel disease (IBD), but are not recommended as long-term therapy. Steroid weaning requires rigorous monitoring of symptoms, which may be cumbersome and lead to missed opportunities. We aim to describe our local quality improvement (QI) initiative to improve and standardize the steroid weaning process.MethodsAfter identifying drivers of steroid weaning, a protocol was developed and implemented for newly diagnosed IBD patients started on steroids and subsequently initiated on anti-TNF-alpha therapy. Interventions included development of a tapering schedule, and standardizing communication with patients and evaluation of symptoms. The primary aim was to increase the percent of patients called on a weekly basis by 20%; secondary aims were to decrease the median steroid days by 25% and to increase the number of our patients weaned off steroids at 8 weeks from 35% to 75% by 1 year after the initiative.ResultsThe median percent of patients called on a weekly basis to assess clinical symptoms and to wean steroids increased to 80% after 1 year. The median number of systemic corticosteroid days decreased from 67.5 to 50.5 days post-protocol implementation with 61.1% patients weaned off by 8 weeks from discharge. Zero patients were admitted for flares with the protocol implementation.ConclusionOur experience illustrates that QI methodology can be used successfully to improve and standardize the steroid weaning process, leading to shortened steroid duration and without increased flares and hospitalizations. What is Known Systemic steroids can be used to induce remission in pediatric IBD patients but should not be used for long term therapy due to abundance of adverse effects. Steroids should be weaned with initiation of long term therapy for pediatric patients with IBD.What is New Standardization of steroid titration protocols through QI methodology prevented missed opportunities for weaning and unnecessary prolongation of steroid duration. Utilization of electronic medical record improves steroid tapering in pediatric IBD.
引用
收藏
页码:76 / 83
页数:8
相关论文
共 50 条
  • [1] Psychological burden and quality of life in newly diagnosed inflammatory bowel disease patients
    Bernabeu, Purificacion
    Belen-Galipienso, Olivia
    van-der Hofstadt, Carlos
    Gutierrez, Ana
    Madero-Velazquez, Lucia
    del Castillo, Gloria Garcia
    Garcia-Sepulcre, Mariana-Fe
    Aguas, Mariam
    Zapater, Pedro
    Rodriguez-Marin, Jesus
    Ruiz-Cantero, Maria-Teresa
    Cameo, Jose I.
    Jover, Rodrigo
    Sempere, Laura
    [J]. FRONTIERS IN PSYCHOLOGY, 2024, 15
  • [2] Anemia in Newly Diagnosed Pediatric Patients with Inflammatory Bowel Disease
    Shentova-Eneva, Rayna
    Kofinova, Denitza
    Hadzhiyski, Petyo
    Yaneva, Penka
    Lazarova, Elena
    Baycheva, Mila
    [J]. GASTROENTEROLOGY INSIGHTS, 2021, 12 (04) : 376 - 383
  • [3] TWEAK is not elevated in patients with newly diagnosed inflammatory bowel disease
    Grimstad, Tore
    Skoie, Inger Marie
    Doerner, Jessica
    Isaksen, Kjetil
    Karlsen, Lars
    Aabakken, Lars
    Omdal, Roald
    Putterman, Chaim
    [J]. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2017, 52 (04) : 420 - 424
  • [4] Fatigue in Newly Diagnosed Inflammatory Bowel Disease
    Grimstad, Tore
    Norheim, Katrine B.
    Isaksen, Kjetil
    Leitao, Kristian
    Hetta, Anne K.
    Carlsen, Arne
    Karlsen, Lars N.
    Skoie, Inger Marie
    Goransson, Lasse
    Harboe, Erna
    Aabakken, Lars
    Omdal, Roald
    [J]. JOURNAL OF CROHNS & COLITIS, 2015, 9 (09): : 725 - 730
  • [5] Osteoporosis in newly diagnosed inflammatory bowel disease
    Qasim, A
    Seery, J
    Morain, CAO
    [J]. GASTROENTEROLOGY, 2001, 121 (02) : 504 - 505
  • [6] Improving venous thromboembolism prophylaxis in patients hospitalized with inflammatory bowel disease: A quality improvement initiative
    Bledsoe, Adam C.
    Quinn, Kevin P.
    Genere, Juan P. Reyes
    Hansel, Stephanie L.
    Raffals, Laura E.
    Kane, Sunanda V.
    [J]. GASTROENTEROLOGY, 2020, 159 (02) : E25 - E25
  • [7] Folate concentrations in pediatric patients with newly diagnosed inflammatory bowel disease
    Heyman, Melvin B.
    Garnett, Elizabeth A.
    Shaikh, Nishat
    Huen, Karen
    Jose, Folashade A.
    Harmatz, Paul
    Winter, Harland S.
    Baldassano, Robert N.
    Cohen, Stanley A.
    Gold, Benjamin D.
    Kirschner, Barbara S.
    Ferry, George D.
    Stege, Erin
    Holland, Nina
    [J]. AMERICAN JOURNAL OF CLINICAL NUTRITION, 2009, 89 (02): : 545 - 550
  • [8] Immunoprofiling of Mucosal Lymphocytes in Patients with Newly Diagnosed Inflammatory Bowel Disease
    Sweeney, Jacob
    McIntire, Patrick
    Yantiss, Rhonda
    Chen, Yao-Tseng
    [J]. MODERN PATHOLOGY, 2018, 31 : 304 - 304
  • [9] Newly diagnosed patients with inflammatory bowel disease are at high risk of osteoporosis
    Abera, H.
    Shah, P.
    D' Souza, R.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2007, 18 : S148 - S148
  • [10] Quality improvement in healthcare for patients with inflammatory bowel disease
    Georgy, Michael
    Negm, Yasser
    El-Matary, Wael
    [J]. TRANSLATIONAL PEDIATRICS, 2019, 8 (01) : 77 - 82